ReviewGastroenterology research and practice2021
Fecal Microbiota Transplantation as Therapy for Treatment of Active Ulcerative Colitis: A Systematic Review and Meta-Analysis.
Review in Gastroenterology research and practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- A Review of Fecal Microbiota Transplantation in Children-Exploring Its Role in the Treatment of Inflammatory Bowel Diseases.Medicina (Kaunas, Lithuania) · 2024Pooled it
- Fecal microbiota transplantation as a therapy for treating ulcerative colitis: an overview of systematic reviews.BMC microbiology · 2023Pooled it
- Pooled it
- From dysbiosis to precision medicine: targeting the microbial-metabolic axis in IBD management.Frontiers in cellular and infection microbiology · 2026Review
- Balancing safety and effectiveness: parent preferences for fecal microbiota transplant and established therapies in pediatric inflammatory bowel disease-results of a multicenter Canadian study.Crohn's & colitis 360 · 2026Article
- A narrative review on fecal microbiota transplantation routes in ulcerative colitis: identifying the optimal approach across key parameters.Annals of medicine and surgery (2012) · 2025Review
- Gut-Heart Axis: The Role of Gut Microbiota and Metabolites in Heart Failure.Circulation research · 2025Review
- A decade of advances in human gut microbiome-derived biotherapeutics.Nature microbiology · 2025Review
- Heart failure-induced microbial dysbiosis contributes to colonic tumour formation in mice.Cardiovascular research · 2024Article
- Article
- Microbiota Therapy in Inflammatory Bowel Disease.Visceral medicine · 2024Review
- Patient preferences for active ulcerative colitis treatments and fecal microbiota transplantation.Therapeutic advances in chronic disease · 2024Article
- Spondyloarthritis with inflammatory bowel disease: the latest on biologic and targeted therapies.Nature reviews. Rheumatology · 2023Review
- Emerging role of the gut microbiome in post-infectious irritable bowel syndrome: A literature review.World journal of gastroenterology · 2023Review
- The Gut Microbial Bile Acid Modulation and Its Relevance to Digestive Health and Diseases.Gastroenterology · 2023Review
- The microbiota and the gut-liver axis in primary sclerosing cholangitis.Nature reviews. Gastroenterology & hepatology · 2023Review
- Effect of Intestinal Microbiota Transplantation on Intestinal Flora and Inflammatory Factor Levels in Patients with Ulcerative Colitis.Infection and drug resistance · 2023Article
- The gut microbiome dysbiosis and regulation by fecal microbiota transplantation: umbrella review.Frontiers in microbiology · 2023Review
- COVID-19 and the Human Gut Microbiome: An Under-Recognized Association.Chonnam medical journal · 2022Review
- Efficacy and safety of fecal microbiota transplantation for the induction of remission in active ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials.Annals of translational medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimIncreasing evidence supports the role of the gut microbiota in the etiology of ulcerative colitis (UC). Fecal microbiota transplantation (FMT) is a highly effective treatment against recurrent Clostridium difficile infection; however, its efficacy in UC is still controversial. A systematic review and meta-analysis was conducted to evaluate the efficacy and safety of FMT for treatment of active UC.
methodsWe searched Cochrane, Medline, Web of Science, and Embase from inception to February 2020. Randomized controlled trials (RCTs) recruiting adults with active UC, which compared FMT with controls, were eligible. The primary outcome was combined clinical remission with endoscopic remission/response. Secondary outcomes included clinical remission, endoscopic remission, and serious adverse events. Relative risk (RR) with 95% confidence interval (CI) is reported.
resultsFive RCTs with 292 participants were eligible for inclusion. When data were pooled for all patients, FMT was associated with a higher combined clinical remission with endoscopic remission/response; the RR of combined outcome not achieving after FMT vs. control was 0.79 (95% CI 0.70-0.88). FMT delivered via lower gastrointestinal route was superior to upper gastrointestinal route with regard to combined clinical remission with endoscopic remission/response (RR = 0.79, 95% CI 0.70-0.89). FMT with pooled donor stool (RR = 0.69, 95% CI 0.56-0.85) and higher frequency of administration (RR = 0.76, 95% CI 0.62-0.93) may be more effective with regard to clinical remission. There was no statistically significant difference in serious adverse events with FMT compared with controls (RR = 0.98, 95% CI 0.93-1.03).
conclusionFMT shows a promising perspective with comparable safety and favorable clinical efficacy for the treatment of active UC in the short term. However, further larger, more rigorously conducted RCTs of FMT in UC are still needed in order to resolve the controversial questions.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.